Inogen 2026 Third Quarter Financial Results - INOGEN INC

Financial Performance:

• Total revenue for Q3 2026 was $77.2 million, a 2.4% decrease year-over-year (3.2% on constant currency), excluding the divested rental business.
• U.S. sales reached $42.2 million, growing 3.8% YoY, driven by distributor demand and new products contributing ~250 basis points.
• International sales were $34.9 million, declining 9% YoY due to reduced capital spending by large European customers.
• Portable Oxygen Concentrator (POC) unit volume increased nearly 6% YoY to 51,900 units and 9.5% Year-to-Date.
• Adjusted gross margin was 44.2% in Q3, down from 45.9% in the prior year period, reflecting lower international sales mix despite manufacturing efficiencies.
• Adjusted operating expenses were $35.3 million, a 4.4% decrease YoY; R&D increased 13.3% to $4.4 million, while SG&A decreased 6.5% to $30.9 million.
• GAAP net loss from continuing operations was $14.8 million, heavily impacted by a $10.6 million non-cash goodwill impairment charge.
• Adjusted net loss from continuing operations was $0.4 million, compared to adjusted net earnings of $1.2 million in the prior year.
• Operating cash flow was negative $4.5 million due to working capital increases; end-of-quarter cash and equivalents totaled $97.7 million with zero debt.
• The company repurchased 1.8 million shares ($11.2 million YTD) and increased share repurchase authorization by $15 million to a total of $45 million.

Guidance and Future Outlook:

• Q4 2026 revenue is guided to $65 million–$68 million, anticipating U.S. growth to offset continued international softness.
• Full-year 2026 revenue from continuing operations is guided to $298 million–$301 million.
• Full-year 2026 adjusted net loss from continuing operations is projected at $7 million–$8 million.
• A new $20 million annualized cost savings program is launching in Q4, aiming for $10 million in savings by end-of-2026 and total annualized savings of >$40 million (combined with divestiture) by end-of-2027.
• The company is shifting its primary earnings metric from Adjusted EBITDA to Adjusted Net Earnings to better reflect profitability post-divestiture.

Business Segments and Product Lines:

• The U.S. Oxygen Rental business was divested on November 2, 2026, for up to $24.8 million in cash consideration expected in H1 2027; results are classified as discontinued operations.
• U.S. POC sales returned to YoY growth for the first time since Q4 2024, signaling recovery in distributor demand.
• Management is expanding the product portfolio into adjacent respiratory markets, specifically sleep and airway clearance, citing the "Aurora" and "Boxy" products as growth drivers.
• Strategic focus is shifting to a leaner organization centered on the core POC business and high-potential adjacent markets.

Market and Competitive Landscape:

• Inogen maintains its status as a market leader in Europe, though capital spending by large European customers remains soft.
• International growth strategy is pivoting to expand beyond Europe into Asia Pacific and Latin America.
• The company cites strong patient and physician loyalty, with patients specifically requesting Inogen products by name.
• Management views current stock valuation as undervalued relative to the company's fundamentals and long-term strategic opportunities.

Risks and Challenges:

• European capital spending weakness and inventory management issues at large customers are the primary headwinds for international revenue.
• Goodwill impairment occurred due to the company's market capitalization falling below stockholders' equity.
• Transition risks associated with the new CEO leadership and organizational restructuring.
• Near-term cash flow pressure driven by working capital fluctuations.

Management Commentary and Tone:

• CEO Andy Redding (newly appointed, previously COO) expressed confidence in the "untapped potential" of the focused business and emphasized urgency, discipline, and execution.
• Tone was realistic regarding current results ("not where they need to be") but optimistic about the path to sustainable profitability.
• Management highlighted the strategic benefit of the rental divestiture in simplifying the business and improving capital efficiency.

Analyst Questions and Answers:

• No live Q&A session was held as this was CEO Andy Redding's first earnings call; he indicated he would connect with investors directly in the coming weeks.
• Management reiterated that the focus is on translating the company's strong assets into consistent financial results and sustained profitability.

Other Key Points:

• The U.S. sales growth was driven by new product traction and increased new patients on POCs.
• The divestiture allows Inogen to direct resources to the highest priority opportunities while improving patient access to its market-leading POCs.
• The company remains disciplined in capital allocation, balancing debt-free liquidity, share repurchases, and growth investments.